



Congrès de **DORYS**


Association de lutte contre la drépanocytose

8 au 10 avril 2019

Bibliothèque Nationale Universitaire de Strasbourg



Auditorium de la Bibliothèque Nationale Universitaire de Strasbourg



THÈMES :

Douleur • Transfusion • Urgences • Réanimation médicale
Greffes/Thérapie Génique • Prise en charge enfants/adultes
Dépistage/Grossesse • Prise en charge Psycho-Sociale

Sessions en français et en anglais



DORYS

Association de lutte
contre la drépanocytose

1a place des orphelins
67000, Strasbourg, France
Tél. +33 6 68 51 90 68
E-mail : dorys.asso@gmail.com



DORYS

Association de lutte
contre la drépanocytose

Informations : Tel. : +33 6 68 51 90 68 ; email : dorys.asso@gmail.com
Inscriptions : congresdorys2019@prodarev.fr

PROGRAMME

Lundi 08 avril

10H15 – 18H30

- Dépistage et épidémiologie
- Psychologie et épidémiologie
- L'Éducation Thérapeutique du Patient
- Rôle des organismes et sociétés
- Rôle des associations

SYMPOSIUM : 12H30 – 13H45

SYMPOSIUM : 17H15 – 18H30


Mardi 09 avril

08H30 – 18H30

- Prise en charge de la douleur
- Prise en charge aux urgences
- Réanimation et drépanocytose
- Transfusion et drépanocytose
- Différents type de greffes /
Thérapie Génique

SYMPOSIUM : 12H30 – 13H45

SYMPOSIUM : 17H15 – 18H30



Mercredi 10 avril

08H30 – 12H30

- Recherches fondamentale et clinique / Études de cas
- Activités physiques et drépanocytose
- E-Santé

SYMPOSIUM : 12H00 – 13H15



Kalpna Gupta,

PhD is a Professor of Medicine in the Division of Hematology, Oncology and Transplantation; and Co-Leader of the Tumor Microenvironment Program in the Masonic Cancer Research Centre at the University of Minnesota, Minneapolis, Minnesota, USA. She obtained her PhD from the All India Institute of Medical Sciences (AIIMS), New Delhi, India. She was an Associate Professor of biochemistry at AIIMS until she moved to the United States.

Recent progress and promise from research on pain in sickle cell disease

Dr Gupta's research focuses on the peripheral and central disease-specific mechanisms of pain. Her laboratory created the paradigm that opioids act on endothelium and other non-neural cells and promote angiogenesis, cancer progression and kidney disease. Her basic findings are under clinical studies/trials currently. One of the current goals of her laboratory is to develop novel strategies and analgesics to treat severe pain without the liabilities of addiction and side-effects. In an effort to develop targeted therapies to treat chronic pain she has developed mouse models to simulate chronic and acute pain in sickle cell disease. Her laboratory has discovered novel targets to improve analgesia, without the inadvertent promotion of primary disease. This led to the understanding of contribution of mast cell activation and neurogenic inflammation to pain in sickle cell anemia. A unique feature of her research is to understand the cross-talk between neural mechanisms and peripheral/systemic disease, which are critical in preventing the inadvertent side effects while developing novel strategies/therapeutics to treat pain. She uses transgenic mouse models of cancer and sickle cell disease to examine opioid/opioid receptor biology and mechanisms of pain.

She recently received the "Science without Borders" award from the Government of Brazil to advance their endeavors in pain research in sickle cell disease.

Dr Gupta is a standing member of the, "Hypertension and Microcirculation" study section and serves as an ad-hoc member for several study sections at NIH and other countries. She is a reviewer for several high impact peer reviewed journals including, Blood, Cancer Res, J Biol Chem, etc. She serves as the co-editor for several journals. She has authored over 60 peer-reviewed publications, several reviews and book chapters.

Dr Gupta is highly involved in the graduate teaching programs for Fellows in Medicine and graduate students in the Cancer Centre. She has mentored several Fellows and Post-docs. She is extremely active in promoting diversity in medicine and has mentored several trainees through NIHs promotion of diversity in medicine program.

She co-leads the Tumor Microenvironment Program at the Masonic cancer Center and the Molecular and Cellular Biomedical Engineering program in the Institute for Engineering in Medicine, at the University of Minnesota.

Anthony James Hall,
MDCM, FACS, FAANS



Application of Medium and High Dose Medical Cannabis for Pain Control in SCD

Anthony Hall was born in Jamaica. He migrated with his family to Ottawa, Toronto, and Montreal where he completed medical school at McGill University.

He completed Internship in General Surgery at Brookdale Hospital in Brooklyn then neurosurgical residencies at the University of Connecticut and the University of Miami.

His practice has been Adult and Pediatric General Neurosurgery with an emphasis on minimally invasive procedures, pain procedures, tumors, and movement disorders.

He is an Assistant Professor at the Herbert Wertheim FIU College of Medicine, an Associate Professor at Nova Southeastern College of Osteopathic Medicine and the College of Allopathic Medicine. He has been a clinical professor for Barry University, the University of Alabama and Visiting Professor at Miami Dade College School of Physician Assistants and Nova Southeastern University School of Physician Assistants. He is certified by the American Board of Neurological Surgery.

Dr. Hall is in private practice in Southeast Florida. He is a member of several professional societies and is the current president of the Miami-Dade County Chapter of the National Medical Association called the James W. Bridges Medical Society.



Lanetta Bronté, MD, MPH, MSPH
*President and Chief Health Officer
The Foundation for SCD Research
Miami, Florida, United States*

Lanetta Bronté, MD, MPH, MSPH, is responsible for strategic planning, scientific, and administrative oversight of the Foundation for Sickle Cell Disease Research (FSCDR).

She is a leading national and international researcher and population health scientist in the field of sickle cell disease, rare blood disorders, community-based participatory research, and chronic disease management. Dr. Bronté has extensive experience in developing programs that are closely aligned with the recruitment and retention of underserved and underrepresented populations for treatment of SCD, research and clinical trials. She is currently President and CEO of the Foundation for Sickle Cell Disease Research (FSCDR), and Chief Wellbeing Officer (CWO) of the Sickle Care and Research Network, FSCDR, LLC, an independent full-service outpatient medical treatment and clinical trials center that offers coordinated care for persons suffering from SCD.

Dr. Bronté is an Associate Professor in the Department of Public Health Sciences, Department of Health Services Research and Policy at the University of Miami's Miller School of Medicine, where she has created a sickle cell disease research portfolio and an academic-community partnership to translate research into practice.

